<li>afatinib<p>atorvastatin increases levels of afatinib by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Reduce afatinib daily dose by 10 mg if not tolerated when coadministered with P-gp inhibitors.</p></li><li>bezafibrate<p>bezafibrate, atorvastatin.
Either increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Increased risk of rhabdomyolysis.</p></li><li>bosutinib<p>atorvastatin increases levels of bosutinib by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug.</p></li><li>carbamazepine<p>carbamazepine will decrease the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>cimetidine<p>cimetidine will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>clarithromycin<p>clarithromycin will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Do not exceed atorvastatin dose of 20 mg/day when coadministered with clarithromycin<span><br><br></span>clarithromycin will increase the level or effect of atorvastatin by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Do not exceed atorvastatin dose of 20 mg/day when coadministered with clarithromycin<span><br><br></span>clarithromycin increases toxicity of atorvastatin by Other (see comment). Avoid or Use Alternate Drug. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>colchicine<p>colchicine, atorvastatin.
Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased risk of rhabdomyolysis (incl a fatality).</p></li><li>cyclosporine<p>cyclosporine will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration increases risk of statin-associated myopathy including rhabdomyolysis</p></li><li>darunavir<p>darunavir will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Limit atorvastatin dose to 20 mg/day</p></li><li>edoxaban<p>atorvastatin will increase the level or effect of edoxaban by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Dose adjustment may be required with strong P-gp inhibitors. DVT/PE treatment: Decrease dose to 30 mg PO once daily. NVAF: No dose reduction recommended</p></li><li>eltrombopag<p>eltrombopag increases toxicity of atorvastatin by Other (see comment). Avoid or Use Alternate Drug. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>eluxadoline<p>atorvastatin increases levels of eluxadoline by decreasing metabolism. Avoid or Use Alternate Drug. Decrease eluxadoline dose to 75 mg PO BID if coadministered with OATP1B1 inhibitors. .</p></li><li>erythromycin base<p>erythromycin base will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.<span><br><br></span>erythromycin base increases toxicity of atorvastatin by Other (see comment). Avoid or Use Alternate Drug. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>erythromycin ethylsuccinate<p>erythromycin ethylsuccinate will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.<span><br><br></span>erythromycin ethylsuccinate increases toxicity of atorvastatin by Other (see comment). Avoid or Use Alternate Drug. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>erythromycin lactobionate<p>erythromycin lactobionate will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.<span><br><br></span>erythromycin lactobionate increases toxicity of atorvastatin by Other (see comment). Avoid or Use Alternate Drug. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>erythromycin stearate<p>erythromycin stearate will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.<span><br><br></span>erythromycin stearate increases toxicity of atorvastatin by Other (see comment). Avoid or Use Alternate Drug. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>everolimus<p>atorvastatin will increase the level or effect of everolimus by  P-glycoprotein (MDR1) efflux transporter. Contraindicated.</p></li><li>fenofibrate<p>fenofibrate, atorvastatin.
Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs.</p></li><li>fenofibrate micronized<p>fenofibrate micronized, atorvastatin.
Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs.</p></li><li>fenofibric acid<p>fenofibric acid, atorvastatin.
Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs.</p></li><li>fosamprenavir<p>fosamprenavir will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Limit atorvastatin dose to 20 mg/day</p></li><li>gemfibrozil<p>gemfibrozil, atorvastatin.
Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Gemfibrozil may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs.</p></li><li>idelalisib<p>idelalisib will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substrates</p></li><li>indinavir<p>indinavir increases toxicity of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Risk of myopathy and rhabdomyolysis increased when atorvastatin coadministered with CYP3A4 inhibitors; use lowest statin dose possible.<span><br><br></span>indinavir increases toxicity of atorvastatin by Other (see comment). Avoid or Use Alternate Drug. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>itraconazole<p>itraconazole will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Limit atorvastatin dose to 20 mg/day</p></li><li>ivacaftor<p>ivacaftor, atorvastatin.
Either increases levels of the other by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Ivacaftor and its M1 metabolite has the potential to inhibit CYP3A4, may significantly increase systemic exposure to CYP3A4 substrates.<span><br><br></span>ivacaftor increases levels of atorvastatin by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Ivacaftor and its M1 metabolite has the potential to inhibit P-gp, may significantly increase systemic exposure to P-gp substrates.</p></li><li>ketoconazole<p>ketoconazole will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.<span><br><br></span>ketoconazole increases toxicity of atorvastatin by Other (see comment). Avoid or Use Alternate Drug. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>mesterolone<p>mesterolone increases toxicity of atorvastatin by decreasing metabolism. Avoid or Use Alternate Drug. Risk of rhabdomyolysis (theoretical interaction based on case reports of combination of danazol and &gt;20 mg/day lovastatin).</p></li><li>mifepristone<p>mifepristone increases toxicity of atorvastatin by Other (see comment). Avoid or Use Alternate Drug. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>nefazodone<p>nefazodone will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>nelfinavir<p>nelfinavir increases toxicity of atorvastatin by Other (see comment). Avoid or Use Alternate Drug. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>niacin<p>niacin, atorvastatin.
Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased risk of rhabdomyolysis (&gt;1 g/day niacin).</p></li><li>ombitasvir/paritaprevir/ritonavir &amp; dasabuvir<p>ombitasvir/paritaprevir/ritonavir &amp; dasabuvir increases toxicity of atorvastatin by Other (see comment). Avoid or Use Alternate Drug. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>pomalidomide<p>atorvastatin increases levels of pomalidomide by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug.</p></li><li>quinidine<p>quinidine will increase the level or effect of atorvastatin by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug.</p></li><li>rifabutin<p>rifabutin will decrease the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>rifampin<p>rifampin will decrease the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>riociguat<p>atorvastatin will increase the level or effect of riociguat by  decreasing metabolism. Avoid or Use Alternate Drug. Coadministration of riociguat (substrate of CYP isoenzymes 1A1, 2C8, 3A, 2J2) with strong CYP inhibitors may require a decreased initial dose of 0.5 mg PO TID; monitor for signs of hypotension and reduce dose if needed</p></li><li>ritonavir<p>ritonavir increases toxicity of atorvastatin by Other (see comment). Avoid or Use Alternate Drug. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>saquinavir<p>saquinavir will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Limit atorvastatin dose to 20 mg/day<span><br><br></span>saquinavir increases toxicity of atorvastatin by Other (see comment). Avoid or Use Alternate Drug. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>sildenafil<p>sildenafil increases toxicity of atorvastatin by Other (see comment). Avoid or Use Alternate Drug. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>st john's wort<p>st john's wort will decrease the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>telithromycin<p>telithromycin increases toxicity of atorvastatin by Other (see comment). Avoid or Use Alternate Drug. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>topotecan<p>atorvastatin will increase the level or effect of topotecan by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Product labeling for PO topotecan recommends avoiding concomitant use of P-gp inhibitors; the interaction with IV topotecan may be less severe but is still likely of clinical significance</p></li><li>venetoclax<p>atorvastatin will increase the level or effect of venetoclax by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. If a P-gp inhibitor must be used, reduce the venetoclax dose by at least 50%. Monitor more closely for signs of venetoclax toxicities.</p></li>